{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,12]],"date-time":"2026-05-12T13:17:05Z","timestamp":1778591825455,"version":"3.51.4"},"reference-count":43,"publisher":"Pleiades Publishing Ltd","issue":"1","license":[{"start":{"date-parts":[[2026,2,1]],"date-time":"2026-02-01T00:00:00Z","timestamp":1769904000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,2,1]],"date-time":"2026-02-01T00:00:00Z","timestamp":1769904000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Dokl Biochem Biophys"],"published-print":{"date-parts":[[2026,2]]},"DOI":"10.1134\/s1607672925700255","type":"journal-article","created":{"date-parts":[[2026,3,30]],"date-time":"2026-03-30T19:15:08Z","timestamp":1774898108000},"page":"99-110","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Evaluation of\u00a0Effectiveness of\u00a0Long-Term Therapy with\u00a0Russian Rituximab Biosimilar (Acellbia) in\u00a0Sjogren\u2019s Disease in\u00a0Real Clinical Practice"],"prefix":"10.1134","volume":"526","author":[{"given":"B. D.","family":"Chaltsev","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"V. I.","family":"Vasilyev","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"A. V.","family":"Torgashina","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yu. I.","family":"Khvan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"E. B.","family":"Rodionova","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"E. I.","family":"Selifanova","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"T. N.","family":"Safonova","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"L. A.","family":"Semenova","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M. V.","family":"Burtseva","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"S. I.","family":"Glukhova","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"137","published-online":{"date-parts":[[2026,3,30]]},"reference":[{"key":"7792_CR1","doi-asserted-by":"publisher","first-page":"989","DOI":"10.1016\/j.berh.2007.09.001","volume":"21","author":"A.G. Tzioufas","year":"2007","unstructured":"Tzioufas, A.G. and Voulgarelis, M., Update on Sj\u00f6gren\u2019s syndrome autoimmune epithelitis: From classification to increased neoplasias, Best Pract. Res. Clin. Rheumatol., 2007, vol. 21, no. 6, pp. 989\u20131010.","journal-title":"Best Pract. Res. Clin. Rheumatol."},{"key":"7792_CR2","unstructured":"Van Ginkel, M.S., Haacke, E.A., Bootsma, H., Arends, S., Van Nimwegen, J.F., Verstappen, G.M., et al., Presence of intraepithelial B-lymphocytes is associated with the formation of lymphoepithelial lesions in salivary glands of primary Sj\u00f6gren\u2019s syndrome patients, Clin. Exp. Rheumatol., 2019, vol. 37, no. 118 (3), pp.\u00a042\u201348."},{"key":"7792_CR3","unstructured":"Safonova, T.N., Vasil\u2019ev, V.I., and Likhvantseva, V.G., Sindrom Shegrena: rukovodstvo dlya vrachei (Sj\u00f6gren\u2019s Syndrome: A Guide for Physicians), Moscow: Izd. Moskovskogo gosudarstvennogo universiteta, 2013."},{"key":"7792_CR4","doi-asserted-by":"publisher","first-page":"3576","DOI":"10.1093\/rheumatology\/keab939","volume":"61","author":"L.G. Chatzis","year":"1981","unstructured":"Chatzis, L.G., Stergiou, I.E., Goules, A.V., Pezoulas, V., Tsourouflis, G., Fotiadis, D., et al., picture, outcome and predictive factors of lymphoma in primary Sj\u00f6gren\u2019s syndrome: Results from a harmonized dataset, Rheumatology (Oxford), 1981, vol. 61, no. 9, pp.\u00a03576\u20133585.","journal-title":"Rheumatology"},{"key":"7792_CR5","doi-asserted-by":"publisher","first-page":"243","DOI":"10.1093\/rheumatology\/keac205","volume":"62","author":"G. Hern\u00e1ndez-Molina","year":"2022","unstructured":"Hern\u00e1ndez-Molina, G., Kostov, B., Brito-Zer\u00f3n, P., Vissink, A., Mandl, T., Hinrichs, A.C., et al., Sj\u00f6gren Big Data Consortium. Characterization and outcomes of 414 patients with primary SS who developed haematological malignancies, Rheumatology (Oxford), 2022, vol. 62, no. 1, pp. 243\u2013255.","journal-title":"Rheumatology"},{"key":"7792_CR6","first-page":"2434","volume":"40","author":"S. Pringle","year":"2022","unstructured":"Pringle, S., Verstappen, G.M., Van Ginkel, M.S., Nakshbandi, U., Girigoria, Z., Bootsma, H., et al., Lymphoepithelial lesions in the salivary glands of primary Sj\u00f6gren\u2019s syndrome patients: The perfect storm?, Clin. Exp. Rheumatol., 2022, vol. 40, no. 12, pp. 2434\u20132442.","journal-title":"Clin. Exp. Rheumatol."},{"key":"7792_CR7","doi-asserted-by":"publisher","first-page":"1541","DOI":"10.1136\/ard.2007.083865","volume":"67","author":"S. Dass","year":"2008","unstructured":"Dass, S., Bowman, S.J., Vital, E.M., Ikeda, K., Pease,\u00a0C.T., Hamburger, J., et al., Reduction of fatigue in Sj\u00f6gren syndrome with rituximab: Results of a randomised, double-blind, placebo-controlled pilot study, Ann. Rheum. Dis., 2008, vol. 67, no. 11, pp. 1541\u20131544.","journal-title":"Ann. Rheum. Dis."},{"key":"7792_CR8","doi-asserted-by":"publisher","first-page":"960","DOI":"10.1002\/art.27314","volume":"62","author":"J.M. Meijer","year":"2010","unstructured":"Meijer, J.M., Meiners, P.M., Vissink, A., Spijkervet, F.K., Abdulahad, W., Kamminga, N., et al., Effectiveness of rituximab treatment in primary Sj\u00f6gren\u2019s syndrome: A\u00a0randomized, double-blind, placebo-controlled trial, Arthritis Rheum., 2010, vol. 62, no. 4, pp.\u00a0960\u2013968.","journal-title":"Arthritis Rheum."},{"key":"7792_CR9","doi-asserted-by":"publisher","first-page":"233","DOI":"10.7326\/M13-1085","volume":"160","author":"V. Devauchelle-Pensec","year":"2014","unstructured":"Devauchelle-Pensec, V., Mariette, X., Jousse-Joulin, S., Berthelot, J.M., Perdriger, A., Pu\u00e9chal, X., et al., Treatment of primary Sj\u00f6gren syndrome with rituximab: A randomized trial, Ann. Intern. Med., 2014, vol.\u00a0160, no. 4, pp. 233\u2013242.","journal-title":"Ann. Intern. Med."},{"key":"7792_CR10","doi-asserted-by":"publisher","first-page":"1440","DOI":"10.1002\/art.40093","volume":"69","author":"S.J. Bowman","year":"2017","unstructured":"Bowman, S.J., Everett, C.C., O\u2019Dwyer, J.L., Emery, P., Pitzalis, C., Ng, W.F., et al., Randomized controlled trial of rituximab and cost-effectiveness analysis in treating fatigue and oral dryness in primary Sj\u00f6gren\u2019s syndrome, Arthritis Rheumatol., 2017, vol. 69, no. 7, pp.\u00a01440\u20131450.","journal-title":"Arthritis Rheumatol."},{"key":"7792_CR11","doi-asserted-by":"publisher","first-page":"1187","DOI":"10.1080\/1744666X.2023.2234641","volume":"19","author":"S. Arends","year":"2023","unstructured":"Arends, S., Verstappen, G.M., De Wolff, L., Pringle, S., Kroese, F., Vissink, A., et al., Why do drug treatments fail in Sj\u00f6gren\u2019s disease? Considerations for treatment, trial design and interpretation of clinical efficacy, Expert Rev. Clin. Immunol., 2023, vol. 19, no. 10, pp.\u00a01187\u20131194.","journal-title":"Expert Rev. Clin. Immunol."},{"key":"7792_CR12","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1136\/annrheumdis-2019-216114","volume":"79","author":"M. Ramos-Casals","year":"2020","unstructured":"Ramos-Casals, M., Brito-Zer\u00f3n, P., Bombardieri, S., Bootsma, H., De Vita, S., D\u00f6rner, T., et al., EULAR-Sj\u00f6gren Syndrome Task Force Group. EULAR recommendations for the management of Sj\u00f6gren\u2019s syndrome with topical and systemic therapies, Ann. Rheum. Dis., 2020, vol. 79, no. 1, pp. 3\u201318.","journal-title":"Ann. Rheum. Dis."},{"key":"7792_CR13","doi-asserted-by":"publisher","first-page":"409","DOI":"10.1093\/rheumatology\/keae152","volume":"64","author":"E.J. Price","year":"2025","unstructured":"Price, E.J., Benjamin, S., Bombardieri, M., Bowman, S., Carty, S., Ciurtin, C., et al., British Society for Rheumatology guideline on management of adult and juvenile onset Sj\u00f6gren disease, Rheumatology (Oxford), 2025, vol. 64, no. 2, pp. 409\u2013439.","journal-title":"Rheumatology"},{"key":"7792_CR14","unstructured":"Flores-Ch\u00e1vez, A., Kostov, B., Solans, R., Fraile, G., Maure, B., Feijoo-Mass\u00f3, C., et al., GEAS-SS SEMI Registry, Severe, life-threatening phenotype of primary Sj\u00f6gren\u2019s syndrome: Clinical characterisation and outcomes in 1580 patients (GEAS-SS Registry), Clin. Exp. Rheumatol., 2018, vol. 36, no. s112 3, pp. 121\u2013129."},{"key":"7792_CR15","first-page":"510","volume":"54","author":"E.L. Nasonov","year":"2016","unstructured":"Nasonov, E.L., Zonova, E.V., Ivanova, O.N., Knyazeva, L.A., Mazurov, V.I., Samigullina, R.R., et al., Results of a phase III comparative clinical trial of rituximab (Acellbia\u00ae and MabThera\u00ae) in rheumatoid arthritis (BIORA study), Nauchno-Prakt. Revmatol., 2016, vol. 54, no. 5, pp. 510\u2013519.","journal-title":"Nauchno-Prakt. Revmatol."},{"key":"7792_CR16","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1002\/art.39859","volume":"69","author":"C.H. Shiboski","year":"2017","unstructured":"Shiboski, C.H., Shiboski, S.C., Seror, R., Criswell, L.A., Labetoulle, M., Lietman, T.M., et al., International Sj\u00f6gren\u2019s Syndrome Criteria Working Group, 2016 American College of Rheumatology, European League Against Rheumatism Classification criteria for primary Sj\u00f6gren\u2019s syndrome: A consensus and data-driven methodology involving three international patient cohorts, Arthritis Rheumatol., 2017, vol. 69, no. 1, pp. 35\u201345.","journal-title":"Arthritis Rheumatol."},{"key":"7792_CR17","doi-asserted-by":"crossref","unstructured":"Seror, R., Bowman, S.J., Brito-Zeron, P., Theander, E., Bootsma, H., Tzioufas, A., et al., EULAR Sj\u00f6gren\u2019s syndrome disease activity index (ESSDAI): A user guide, RMD Open, 2015, vol. 1, no. 1, p. e000022.","DOI":"10.1136\/rmdopen-2014-000022"},{"key":"7792_CR18","doi-asserted-by":"publisher","first-page":"e404","DOI":"10.4317\/medoral.24736","volume":"26","author":"C. Alvari\u00f1o","year":"2021","unstructured":"Alvari\u00f1o, C., Bagan, L., Murillo-Cortes, J., Calvo, J., and Bagan, J., Stimulated whole salivary flow rate: The most appropriate technique for assessing salivary flow in Sj\u00f6gren syndrome, Med. Oral Patol. Oral Cir. Bucal, 2021, vol. 26, no. 3, pp. e404\u2013e407.","journal-title":"Med. Oral Patol. Oral Cir. Bucal"},{"key":"7792_CR19","doi-asserted-by":"publisher","first-page":"295","DOI":"10.1177\/000348945606500201","volume":"65","author":"I.M. Blatt","year":"1956","unstructured":"Blatt, I.M., French, A.J., Holt, J.F., Maxwell, J.H., and Rubin, P., Secretory sialography in diseases of the major salivary glands, Ann. Otol. Rhinol. Laryngol., 1956, vol. 65, no. 2, pp. 295\u2013317.","journal-title":"Ann. Otol. Rhinol. Laryngol."},{"key":"7792_CR20","doi-asserted-by":"publisher","first-page":"967","DOI":"10.1136\/annrheumdis-2019-215024","volume":"78","author":"S. Jousse-Joulin","year":"2019","unstructured":"Jousse-Joulin, S., D\u2019Agostino, M.A., Nicolas, C., Naredo, E., Ohrndorf, S., Backhaus, M., et al., Video clip assessment of a salivary gland ultrasound scoring system in Sj\u00f6gren\u2019s syndrome using consensual definitions: An OMERACT ultrasound working group reliability exercise, Ann. Rheum. Dis., 2019, vol. 78, no. 7, pp. 967\u2013973.","journal-title":"Ann. Rheum. Dis."},{"key":"7792_CR21","doi-asserted-by":"publisher","first-page":"1161","DOI":"10.1136\/annrheumdis-2016-210448","volume":"76","author":"B.A. Fisher","year":"2017","unstructured":"Fisher, B.A., Jonsson, R., Daniels, T., Bombardieri, M., Brown, R.M., and Morgan, P., Sj\u00f6gren\u2019s histopathology workshop group (appendix) from ESSENTIAL (EULAR Sj\u00f6gren\u2019s syndrome study group). Standardisation of labial salivary gland histopathology in clinical trials in primary Sj\u00f6gren\u2019s syndrome, Ann. Rheum. Dis., 2017, vol. 76, no. 7, pp. 1161\u20131168.","journal-title":"Ann. Rheum. Dis."},{"key":"7792_CR22","doi-asserted-by":"publisher","first-page":"405","DOI":"10.1016\/j.ajo.2009.09.013","volume":"149","author":"J.P. Whitcher","year":"2010","unstructured":"Whitcher, J.P., Shiboski, C.H., Shiboski, S.C., Heidenreich, A.M., Kitagawa, K., Zhang, S., et al., Sj\u00f6gren\u2019s International Collaborative Clinical Alliance Research Groups. A simplified quantitative method for assessing keratoconjunctivitis sicca from the Sj\u00f6gren\u2019s Syndrome International Registry, Am. J. Ophthalmol., 2010, vol. 149, no. 3, pp. 405\u2013415.","journal-title":"Am. J. Ophthalmol."},{"key":"7792_CR23","doi-asserted-by":"crossref","unstructured":"Verstappen, G.M., Ice, J.A., Bootsma, H., Pringle, S., Haacke, E.A., De Lange, K., et al., Gene expression profiling of epithelium-associated FcRL4+ B cells in primary Sj\u00f6gren\u2019s syndrome reveals a pathogenic signature, J. Autoimmun., 2020, vol. 109, p. 102439.","DOI":"10.1016\/j.jaut.2020.102439"},{"key":"7792_CR24","doi-asserted-by":"crossref","unstructured":"Chatzis, L., Goules, A.V., Pezoulas, V., Baldini, C., Gandolfo, S., Skopouli, F.N., et al., A biomarker for lymphoma development in Sjogren\u2019s syndrome: Salivary gland focus score, J. Autoimmun., 2021, vol. 121, p.\u00a0102648.","DOI":"10.1016\/j.jaut.2021.102648"},{"key":"7792_CR25","doi-asserted-by":"publisher","first-page":"e553","DOI":"10.1016\/S2665-9913(21)00122-3","volume":"3","author":"S. Arends","year":"2021","unstructured":"Arends, S., De Wolff, L., Van Nimwegen, J.F., Verstappen, G., Vehof, J., Bombardieri, M., et al., Composite of Relevant Endpoints for Sj\u00f6gren\u2019s Syndrome (CRESS): development and validation of a novel outcome measure, Lancet Rheumatol., 2021, vol. 3, no. 8, pp. e553\u2013e562.","journal-title":"Lancet Rheumatol."},{"key":"7792_CR26","doi-asserted-by":"publisher","first-page":"979","DOI":"10.1136\/annrheumdis-2021-222054","volume":"81","author":"R. Seror","year":"2022","unstructured":"Seror, R., Baron, G., Camus, M., Cornec, D., Perrodeau, E., Bowman, S.J., et al., NECESSITY WP5-STAR development working group. Dev. and preliminary validation of the Sj\u00f6gren\u2019s Tool for Assessing Response (STAR): A consensual composite score for assessing treatment effect in primary Sj\u00f6gren\u2019s syndrome, Ann. Rheum. Dis., 2022, vol. 81, no. 7, pp. 979\u2013989.","journal-title":"Ann. Rheum. Dis."},{"key":"7792_CR27","doi-asserted-by":"publisher","first-page":"412","DOI":"10.1136\/annrheumdis-2017-212268","volume":"77","author":"B.A. Fisher","year":"2018","unstructured":"Fisher, B.A., Everett, C.C., Rout, J., O\u2019Dwyer,\u00a0J.L., Emery,\u00a0P., Pitzalis,\u00a0C., et al., Effect of rituximab on a salivary gland ultrasound score in primary Sj\u00f6gren\u2019s syndrome: Results of the TRACTISS randomised double-blind multicentre substudy, Ann. Rheum. Dis., 2018, vol. 77, no. 3, pp. 412\u2013416.","journal-title":"Ann. Rheum. Dis."},{"key":"7792_CR28","doi-asserted-by":"publisher","first-page":"1464","DOI":"10.1002\/art.22603","volume":"56","author":"J.O. Pers","year":"2007","unstructured":"Pers, J.O., Devauchelle, V., Daridon, C., Bendaoud, B., Le Berre, R., Bordron, A., et al., BAFF-modulated repopulation of B lymphocytes in the blood and salivary glands of rituximab-treated patients with Sj\u00f6gren\u2019s syndrome, Arthritis Rheum., 2007, vol. 56, no. 5, pp. 1464\u20131477.","journal-title":"Arthritis Rheum."},{"key":"7792_CR29","doi-asserted-by":"publisher","first-page":"102","DOI":"10.1016\/j.jaut.2015.11.002","volume":"67","author":"D. Cornec","year":"2016","unstructured":"Cornec, D., Costa, S., Devauchelle-Pensec, V., Jousse-Joulin, S., Marcorelles, P., Berthelot, J.M., et\u00a0al., Blood and salivary-gland BAFF-driven B-cell hyperactivity is associated to rituximab inefficacy in primary Sj\u00f6gren\u2019s syndrome, J. Autoimmun., 2016, vol.\u00a067, pp. 102\u2013110.","journal-title":"J. Autoimmun."},{"key":"7792_CR30","doi-asserted-by":"publisher","first-page":"1933","DOI":"10.1136\/annrheumdis-2015-208304","volume":"75","author":"K. Delli","year":"2016","unstructured":"Delli, K., Haacke, E.A., Kroese, F.G., Pollard, R.P., Ihrler, S., van der Vegt, B., et al., Towards personalised treatment in primary Sj\u00f6gren\u2019s syndrome: Baseline parotid histopathology predicts responsiveness to rituximab treatment, Ann. Rheum. Dis., 2016, vol. 75, no. 11, pp. 1933\u20131938.","journal-title":"Ann. Rheum. Dis."},{"key":"7792_CR31","doi-asserted-by":"publisher","first-page":"90","DOI":"10.1016\/j.jaut.2017.03.012","volume":"81","author":"E.A. Haacke","year":"2017","unstructured":"Haacke, E.A., Bootsma, H., Spijkervet, F., Visser, A., Vissink, A., Kluin, P.M., et al., FcRL4+ B-cells in salivary glands of primary Sj\u00f6gren\u2019s syndrome patients, J.\u00a0Autoimmun., 2017, vol. 81, pp. 90\u201398.","journal-title":"J.\u00a0Autoimmun."},{"key":"7792_CR32","doi-asserted-by":"publisher","first-page":"763","DOI":"10.1002\/art.42772","volume":"76","author":"E. Pontarini","year":"2024","unstructured":"Pontarini, E., Sciacca, E., Chowdhury, F., Grigoriadou, S., Rivellese, F., Murray-Brown, W.J., et al., Trial for Anti-B Cell Therapy in Patients with Primary Sj\u00f6gren Syndrome Study Research Group. Serum and tissue biomarkers associated with Composite of Relevant Endpoints for Sj\u00f6gren Syndrome (CRESS) and Sj\u00f6gren Tool for Assessing Response (STAR) to B cell-targeted therapy in the Trial of Anti-B Cell Therapy in Patients with Primary Sj\u00f6gren Syndrome (TRACTISS), Arthritis Rheumatol., 2024, vol. 76, no. 5, pp. 763\u2013776.","journal-title":"Arthritis Rheumatol."},{"key":"7792_CR33","doi-asserted-by":"publisher","first-page":"1586","DOI":"10.1093\/rheumatology\/keac470","volume":"62","author":"S. De Vita","year":"2023","unstructured":"De Vita, S., Isola, M., Baldini, C., Goules, A.V., Chatzis, L.G., Quartuccio, L., et al., Predicting lymphoma in Sj\u00f6gren\u2019s syndrome and the pathogenetic role of parotid microenvironment through precise parotid swelling recording, Rheumatology (Oxford), 2023, vol. 62, no. 4, pp. 1586\u20131593.","journal-title":"Rheumatology"},{"key":"7792_CR34","doi-asserted-by":"publisher","first-page":"1586","DOI":"10.1002\/art.39085","volume":"67","author":"E.M. Vital","year":"2015","unstructured":"Vital, E.M., Wittmann, M., Edward, S., Md Yusof, M.Y., MacIver, H., Pease, C.T., et al., Brief report: Responses to rituximab suggest B cell-independent inflammation in cutaneous systemic lupus erythematosus, Arthritis Rheumatol., 2015, vol. 67, no. 6, pp. 1586\u20131591.","journal-title":"Arthritis Rheumatol."},{"key":"7792_CR35","doi-asserted-by":"publisher","first-page":"208","DOI":"10.1097\/BOR.0000000000000704","volume":"32","author":"H. Shi","year":"2020","unstructured":"Shi, H., Gudjonsson, J.E., and Kahlenberg, J.M., Treatment of cutaneous lupus erythematosus: Current approaches and future strategies, Curr. Opin. Rheumatol., 2020, vol. 32, no. 3, pp. 208\u2013214.","journal-title":"Curr. Opin. Rheumatol."},{"key":"7792_CR36","doi-asserted-by":"publisher","first-page":"222","DOI":"10.1002\/art.27233","volume":"62","author":"J.T. Merrill","year":"2010","unstructured":"Merrill, J.T., Neuwelt, C.M., Wallace, D.J., Shanahan, J.C., Latinis, K.M., Oates, J.C., et al., Efficacy and safety of rituximab in moderately-to-severely active systemic lupus erythematosus: The randomized, double-blind, phase II\/III systemic lupus erythematosus evaluation of rituximab trial, Arthritis Rheum., 2010, vol. 62, no. 1, pp. 222\u2013233.","journal-title":"Arthritis Rheum."},{"key":"7792_CR37","doi-asserted-by":"publisher","first-page":"1215","DOI":"10.1002\/art.34359","volume":"64","author":"B.H. Rovin","year":"2012","unstructured":"Rovin, B.H., Furie, R., Latinis, K., Looney, R.J., Fervenza, F.C., Sanchez-Guerrero, J., et al., LUNAR Investigator Group, Efficacy and safety of rituximab in patients with active proliferative lupus nephritis: The Lupus Nephritis Assessment with Rituximab study, Arthritis Rheum., 2012, vol. 64, no. 4, pp. 1215\u20131226.","journal-title":"Arthritis Rheum."},{"key":"7792_CR38","doi-asserted-by":"publisher","first-page":"517","DOI":"10.1002\/acr.22968","volume":"69","author":"S.E. Carsons","year":"2017","unstructured":"Carsons, S.E., Vivino, F.B., Parke, A., Carteron, N., Sankar, V., Brasington, R., et al., Treatment guidelines for rheumatologic manifestations of Sj\u00f6gren\u2019s syndrome: Use of biologic agents, management of fatigue, and inflammatory musculoskeletal pain, Arthritis Care Res. (Hoboken), 2017, vol. 69, no. 4, pp. 517\u2013527.","journal-title":"Arthritis Care Res."},{"key":"7792_CR39","doi-asserted-by":"publisher","first-page":"407","DOI":"10.1136\/ard-2023-224999","volume":"83","author":"M. Pezot","year":"2024","unstructured":"Pezot, M., Nocturne, G., Belkhir, R., Henry, J., Pavy, S., Seror, R., et al., Obinutuzumab in patients with Sjogren\u2019s disease immunised against rituximab, Ann. Rheum. Dis., 2024, vol. 83, no. 3, pp. 407\u2013408.","journal-title":"Ann. Rheum. Dis."},{"key":"7792_CR40","doi-asserted-by":"crossref","unstructured":"Mariette, X., Barone, F., Baldini, C., Bootsma, H., Clark, K.L., De Vita, S., et al., A randomized, phase II study of sequential belimumab and rituximab in primary Sj\u00f6gren\u2019s syndrome, JCI Insight, 2022, vol. 7, no. 23, p. e163030.","DOI":"10.1172\/jci.insight.163030"},{"key":"7792_CR41","doi-asserted-by":"publisher","first-page":"161","DOI":"10.1016\/S0140-6736(21)02251-0","volume":"399","author":"S.J. Bowman","year":"2022","unstructured":"Bowman, S.J., Fox, R., D\u00f6rner, T., Mariette, X., Papas, A., Grader-Beck, T., et al., Safety and efficacy of subcutaneous ianalumab (VAY736) in patients with primary Sj\u00f6gren\u2019s syndrome: A randomised, double-blind, placebo-controlled, phase 2b dose-finding trial, Lancet, 2022, vol. 399, no. 10320, pp. 161\u2013171.","journal-title":"Lancet"},{"key":"7792_CR42","doi-asserted-by":"publisher","first-page":"1075","DOI":"10.1093\/rheumatology\/key428","volume":"58","author":"T.H. Ramwadhdoebe","year":"2019","unstructured":"Ramwadhdoebe, T.H., Van Baarsen, L.G.M., Boumans, M.J.H., Bruijnen, S.T.G., Safy, M., Berger, F.H., et al., Effect of rituximab treatment on T and B cell subsets in lymph node biopsies of patients with rheumatoid arthritis, Rheumatology (Oxford), 2019, vol. 58, no. 6, pp. 1075\u20131085.","journal-title":"Rheumatology"},{"key":"7792_CR43","first-page":"262","volume":"62","author":"E.L. Nasonov","year":"2024","unstructured":"Nasonov, E.L., Rumyantsev, A.G., and Samsonov, M.Yu., Pharmacotherapy of autoimmune rheumatic diseases\u2014from monoclonal antibodies to CAR-T cells: 20\u00a0years later, Nauchno-Prakt. Revmatol., 2024, vol. 62, no. 3, pp. 262\u2013279.","journal-title":"Nauchno-Prakt. Revmatol."}],"container-title":["Doklady Biochemistry and Biophysics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1134\/S1607672925700255.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1134\/S1607672925700255","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1134\/S1607672925700255.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,12]],"date-time":"2026-05-12T12:49:33Z","timestamp":1778590173000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1134\/S1607672925700255"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2]]},"references-count":43,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2026,2]]}},"alternative-id":["7792"],"URL":"https:\/\/doi.org\/10.1134\/s1607672925700255","relation":{},"ISSN":["1607-6729","1608-3091"],"issn-type":[{"value":"1607-6729","type":"print"},{"value":"1608-3091","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,2]]},"assertion":[{"value":"20 October 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 October 2025","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 November 2025","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 March 2026","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"All procedures performed in studies involving human participants complied with the ethical standards of the institutional and\/or national research ethics committee and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards. The study was approved by the Ethics Committee of the Nasonova Research Institute of Radiology (protocol no. 4 dated February 15, 2018). Informed consent was obtained from each participant included in the study.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"ETHICS APPROVAL AND CONSENT TO PARTICIPATE"}},{"value":"The authors of this work declare that they have no conflicts of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"CONFLICT OF INTEREST"}}]}}